Kras is one of the most commonly activated oncogenes in human cancer, with 17 to 25% of all human tumors harboring an activating Kras mutation29 In addition to gastrointestinal tumors, over 90% of pancreatic adenocarcinomas, 30%–50% of colorectal cancers, 55% of thyroid cancers, 35% of lung cancers, and 35% of rhabdomyosarcomas harbor mutated RAS genes30. The gene discussed is KRAS; the disease is thyroid gland carcinoma.